Brand Name
Zykadia
Generic Name
Ceritinib
View Brand Information FDA approval date: March 18, 2019
Classification: Kinase Inhibitor
Form: Tablet
What is Zykadia (Ceritinib)?
ZYKADIA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase -positive as detected by an FDA-approved test [see Dosage and Administration.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma
Summary: A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Population Pharmacokinetics, Effectiveness and Safety of Antineoplastic Drugs in Elderly Patients
Summary: The purpose is to study the population pharmacokinetics, effectiveness and safety of antineoplastic drugs (Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib, Imatinib, Lapatinib, etc) in elderly patients and recommend optimized dosage regimens.